Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Franco Castillo Tokumori, MD, Chetasi Talati, MD, Najla E. Al Ali, David A. Sallman, MD, Seongseok Yun, MDPhD, Kendra L. Sweet, MD MS, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD, Andrew T. Kuykendall, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-140145

Published: 2020

Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138833

Published: 2020

Journal Articles

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

Amy Song, Omar Altabbakh, BS, David A. Sallman, MD, Eric Padron, MD, Chetasi Talati, MD, Mohammad O Hussaini, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142615

Published: 2020

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

David A. Sallman, MD, Hany Elmariah, MD MS, Kendra L. Sweet, MD MS, Chetasi Talati, MD, Asmita Mishra, MD, Linda L. Kelley, PhD, Amy Lankford, PhD, Tim Chan, PhD, Rutul R Shah, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Helen Sabzevari, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139417

Published: 2020

Journal Articles

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Seongseok Yun, MDPhD, David Gajzer, MD, Najla Al Ali, M.Sc, Nicole D. Vincelette, PhD, Pukhraz Basra, MBBS, Chetasi Talati, MD, Andrew T. Kuykendall, MD, Eric Padron, MD, Kendra Sweet, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137116

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Mohammad O Hussaini, MD, David A. Sallman, MD, Dana Elise Rollison, PhD, Eric Padron, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139710

Published: 2020

Journal Articles

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Gregory A. Abel, MD MPH, Donnie Hebert, PhD, Cecilia Lee, DrPH, RN, James M. Foran, MD, Steven D. Gore, MD, Wael Saber, MD MS, Dana Elise Rollison, PhD, Eric Padron, MD, Steffanie H. Wilson, PhD, Jason Thompson, MS, MBA, Myron Waclawiw, PhD, Nancy L. DiFronzo, PhD, Mikkael A. Sekeres

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136992

Published: 2020

Journal Articles

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Onyee Chan, MD, Najla Al Ali, MD, David A. Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141960

Published: 2020

Journal Articles

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Roger Belizaire, MD PhD, Sebastian Koochaki, BS, MS, Namrata Udeshi, PhD, Alexis Vedder, BS, Lei Sun, Monica Schenone, PhD, Steven Carr, PhD, Eric Padron, MD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 563.

https://doi.org/10.1182/blood-2019-122503

Published: 2019

Journal Articles

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 676.

https://doi.org/10.1182/blood-2019-131055

Published: 2019

Journal Articles

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Anthony Hunter, MD, Chetasi Talati, MD, David A Sallman, MD, Hannah Asghari, MD BS, Jinming Song, MD PhD, Mohammad Hussaini, MD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Andrew T Kuykendall, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Asmita Mishra, MD

Blood (2019) 134 (Supplement_1): 149.

https://doi.org/10.1182/blood-2019-131530

Published: 2019

Journal Articles

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Pukhraz Basra, MBBS, David Gajzer, MD, Mohammad O Hussaini, MD, Hailing Zhang, MD, Lynn C. Moscinski, MD, Eric Padron, MD, David A Sallman, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Jinming Song, MD PhD

Blood (2019) 134 (Supplement_1): 5428.

https://doi.org/10.1182/blood-2019-132070

Published: 2019

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Blood (2019) 134 (Supplement_1): 4220.

https://doi.org/10.1182/blood-2019-128165

Published: 2019

Journal Articles

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Eric Padron, MD, David A Sallman, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4177.

https://doi.org/10.1182/blood-2019-123536

Published: 2019

Journal Articles

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Anthony M. Hunter, MD, Nelson Ryan, PharmD, Mohammad Hussaini, MD, Ratilal Akabari, Alan F. List, MD, Jeffrey Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Javier Pinilla Ibarz, MD PhD, Andrew T Kuykendall, MD, Ling Zhang, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4167.

https://doi.org/10.1182/blood-2019-130196

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

https://doi.org/10.1182/blood-2019-126967

Published: 2019

NARROW

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only